A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 587-594

  Khalili, Davood ^a,b   Asgari, Samaneh ^a   Hadaegh, Farzad ^a   Steyerberg, Ewout W ^c   Rahimi, Kazem ^d   Fahimfar, Noushin ^e   Azizi, Fereidoun ^f  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular diseases; Net benefit; Number needed to treat; Prevention; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DIABETIC PATIENT; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; VALIDATION PROCESS; CARDIOLOGY; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; HEALTH SURVEY; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; RISK FACTOR; STANDARDS; UNITED STATES;

ADULT; AGED; AMERICAN HEART ASSOCIATION; CARDIOLOGY; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; UNITED STATES;

EID: 84933563947     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.067     Document Type: Article

References (33)

1. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. The pooling project research group, J. Chronic Dis. 31 (1978) 201-306.
2. D.C. Goff Jr., D.M. Lloyd-Jones, G. Bennett, et al., ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation 2013 (2013).
3. N.J. Stone, J. Robinson, A.H. Lichtenstein, et al., ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation 2013 (2013).
4. D.M. Lloyd-Jones, D. Goff, N.J. Stone, Statins, risk assessment, and the new American prevention guidelines, Lancet 383 (2013) 600-602.
5. P.M. Ridker, N.R. Cook, Statins: new American guidelines for prevention of cardiovascular disease, Lancet 382 (2013) 1762-1765.
6. S.S. Martin, R.S. Blumenthal, Concepts and controversies: the 2013 American College of Cardiology/American Heart Association Risk Assessment and Cholesterol Treatment Guidelines, Ann. Intern. Med. 160 (2014) 356-358.
7. J.P. Ioannidis, More than a billion people taking statins?: potential implications of the new cardiovascular guidelines, JAMA 311 (2014) 463-464.
8. M. Myerson, R.S. Rosenson, 2013 ACC/AHA guideline: a guideline for the population - without evidence from the population, Cardiovasc. Drugs Ther. 28 (2014) 203-204.
9. D. Khalili, F. Hadaegh, H. Soori, E.W. Steyerberg, M. Bozorgmanesh, F. Azizi, Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study, Am. J. Epidemiol. 176 (2012) 177-186.
10. R.B. D'Agostino Sr., M.J. Pencina, Invited commentary: clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance, Am. J. Epidemiol. 176 (2012) 187-189.
11. F. Azizi, M. Rahmani, H. Emami, et al., Cardiovascular risk factors in an Iranian urban population: Tehran Lipid and Glucose Study (phase 1), Soz. Praventivmed. 47 (2002) 408-426.
12. F. Azizi, A. Ghanbarian, A.A. Momenan, et al., Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II, Trials 10 (2009) 5.
13. A. Nejat, M. Mirbolouk, R. Mohebi, et al., Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study, Clin. Biochem. 47 (2014) 1239-1244.
14. Y. Chen, X. Zhang, B. Pan, et al., A modified formula for calculating low-density lipoprotein cholesterol values, Lipids Health Dis. 9 (2010) 52.
15. D. Khalili, A. Mosavi-Jarrahi, F. Eskandari, et al., Evaluation of cause of deaths' validity using outcome measures from a prospective, population based cohort study in Tehran, Iran, PLoS One 7 (2012) e31427.
16. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, et al., Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 ACC/AHA cholesterol guideline, Ann. Intern. Med. 160 (2014) 339-343.
17. E.W. Steyerberg, Clinical Prediction Models. A Practical Approach to Development, Validation, and Updating, Springer, New York, 2009.
18. A.J. Vickers, Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers, Am. Stat 62 (2008) 314-320.
19. A.J. Vickers, A.M. Cronin, E.B. Elkin, M. Gonen, Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers, BMC Med. Inform. Decis. Mak. 8 (2008) 53.
20. S.G. Baker, N.R. Cook, A. Vickers, B.S. Kramer, Using relative utility curves to evaluate risk prediction, J. R. Stat Soc. Ser. A Stat Soc. 172 (2009) 729-748.
21. S.G. Baker, B. Van Calster, E.W. Steyerberg, Evaluating a new marker for risk prediction using the test tradeoff: an update, Int. J. Biostat 8 (2012).
22. P. Muntner, M.M. Safford, M. Cushman, G. Howard, Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation, Circulation 129 (2014) 266-267.
23. M.J. Pencina, A.M. Navar-Boggan, R.B. D'Agostino Sr., et al., Application of new cholesterol guidelines to a population-based sample, N. Engl. J. Med. 370 (2014) 1422-1431.
24. CL. Shufelt, J.E. Manson, Statin therapy in women, Menopause 21 (2014) 896-898.
25. D. Khalili, F.H. Sheikholeslami, M. Bakhtiyari, F. Azizi, A.A Momenan, F. Hadaegh, The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: a 10-year population-based cohort study, PLoS One 9 (2014) e105804.
26. Third Report of the National Cholesterol Education Program (NCEP), Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report, Circulation 106 (2002) 3143-3421.
27. T.P. Murphy, R. Dhangana, M.J. Pencina, A.M. Zafar, R.B. D'Agostino, Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment, Atherosclerosis 216 (2011) 452-457.
28. M. Kavousi, M.J. Leening, D. Nanchen, et al., Comparison of application of the ACC/ AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort, JAMA 311 (2014) 1416-1423.
29. K.M. Johnson, DA Dowe, Accuracy of statin assignment using the 2013 AHA/ACC cholesterol guideline versus the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging, J. Am Coll. Cardiol. 64 (2014) 910-919.
30. K.K. Ray, J.J.P. Kastelein, S.M. Boekholdt, et al., The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011, Eur. Heart J. (2014) ehu107.
31. J. Vaucher, P. Marques-Vidal, M. Preisig, Waeber Gr, P. Vollenweider, Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease, Eur. Heart J. (2014) ehu064
32. H. Janes, M. Pepe, Re: "clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study", Am. J. Epidemiol. 177 (2013) 864-865.
33. D. Khalili, F. Hadaegh, E.W. Steyerberg, The authors reply, Am. J. Epidemiol. 177 (2013) 865-866.